Immuno-Oncology Institute Aims to Advance Access to Therapies in Community Setting

Share this content:
The ACCC has launched Institute for Clinical Immuno-Oncology in order to promote the advancement of access to therapies.
The ACCC has launched Institute for Clinical Immuno-Oncology in order to promote the advancement of access to therapies.

The Association of Community Cancer Centers (ACCC) has launched the Institute for Clinical Immuno-Oncology (ICLIO) in order to promote the advancement of access to immuno-oncology therapies, particularly in the community care setting.

To facilitate the adoption of immuno-oncology in the community cancer setting, ICLIO will educate medical professionals on the best practices for integrating immuno-oncology into clinical care, insurance and reimbursement, social work, and patient access to novel treatment options.

Resources for the multidisciplinary team include a monthly e-newsletter, monthly e-courses, the ICLIO Scholars Program, the ICLIO White Paper, and the ICLIO National Education Conference.

RELATED: Immunotherapies Shine at ASCO Annual Meeting

Providers with membership to ACCC, who are estimated to treat over 60% of all patients with cancer, will also have access to ICLIO. 

ICLIO is chaired by Lee S. Schwartzberg, MD, FACP, Chief of the Division of Hematology and Oncology at The West Clinic and Professor of Medicine at the University of Tennessee in Memphis.

Reference

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters